Export financials
Inozyme Pharma (INZY)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Inozyme Pharma Financial Statements 2024-2011 | INZY
Annual Financial Statements Inozyme Pharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 297 M | 102 M | 161 M | 381 M | - | - | - | - | - | - | - | - | - |
Shares |
62.8 M | 51.8 M | 37.8 M | 23.6 M | 18.1 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
- | 5.72 | 2.69 | 6.82 | 20.6 | - | - | - | - | - | - | - | - | - |
Net Income |
-102 M | -71.2 M | -67.1 M | -56.6 M | -56.4 M | -19.7 M | -6.96 M | - | - | - | - | - | - | - |
Operating Income |
-104 M | -75.6 M | -68.7 M | -56.6 M | -57 M | -20.8 M | - | - | - | - | - | - | - | - |
Interest Expense |
-102 K | -28 K | 262 K | -189 K | 247 K | -24 K | - | - | - | - | - | - | - | - |
EBITDA |
-103 M | -74.8 M | -68 M | -56 M | -56.8 M | -20.7 M | -11.6 M | - | - | - | - | - | - | - |
Operating Expenses |
104 M | 75.6 M | 68.7 M | 56.6 M | 57 M | 20.8 M | 11.6 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
20.8 M | 20.8 M | 20.8 M | 18.9 M | 10.5 M | 4.59 M | 3.49 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Inozyme Pharma
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
64.3 M | 64.2 M | 63.3 M | 61.9 M | 61.8 M | 61.8 M | 56.8 M | 44.9 M | 43.7 M | 40.4 M | 43.7 M | 39.7 M | 23.7 M | 23.7 M | 23.6 M | 23.5 M | 23.4 M | 23.4 M | 18.1 M | 1.25 M | 1.21 M | 1.2 M | 1.2 M | 1.17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-28 M | - | -24.6 M | -27 M | -23.3 M | - | -16.6 M | -15.6 M | -17.4 M | - | -16.4 M | -15.3 M | -16.9 M | - | -14.3 M | -12.5 M | -11 M | - | 56.4 M | -56.4 M | -56.4 M | - | -19.7 M | -19.7 M | -4.97 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-27.7 M | - | -24.9 M | -27.7 M | -24.3 M | - | -18.1 M | -16.4 M | -18.4 M | - | -16.9 M | -15.4 M | -16.8 M | - | -14.3 M | -12.7 M | -11 M | - | -28.3 M | -9.55 M | -7.91 M | - | -4.32 M | -4.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-62 K | - | -81 K | 1.4 M | -51 K | - | 20 K | 771 K | 328 K | - | -197 K | -191 K | -105 K | - | -65 K | 57 K | -141 K | - | 157 K | 4 K | -3 K | - | -3 K | -14 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-27.5 M | - | - | - | -24.2 M | - | - | - | -18.2 M | - | -16.7 M | -15.2 M | -16.7 M | - | -14.1 M | -12.5 M | -10.8 M | - | -28.3 M | -9.52 M | -7.88 M | - | -4.3 M | -4.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
27.7 M | - | 24.9 M | 27.7 M | 24.3 M | - | 18.1 M | 16.4 M | 18.4 M | - | 16.9 M | 15.4 M | 16.8 M | - | 14.3 M | 12.7 M | 11 M | - | 28.3 M | 9.55 M | 7.91 M | - | 4.32 M | 4.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
5.41 M | - | 4.96 M | 5.91 M | 5.23 M | - | 4.73 M | 4.73 M | 6.51 M | - | 4.72 M | 5.38 M | 5.02 M | - | 4.92 M | 4.44 M | 4.37 M | - | 3.14 M | 1.67 M | 1.5 M | - | 1 M | 1.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Main types of financial statements Inozyme Pharma INZYFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Inozyme Pharma plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Agios Pharmaceuticals
AGIO
|
$ 33.25 | 0.78 % | $ 1.93 B | ||
|
Amarin Corporation plc
AMRN
|
$ 13.0 | 0.08 % | $ 5.39 B | ||
|
MeiraGTx Holdings plc
MGTX
|
$ 11.0 | 0.49 % | $ 885 M | ||
|
Passage Bio
PASG
|
$ 4.5 | 4.39 % | $ 14.4 M | ||
|
AbbVie
ABBV
|
$ 261.59 | 0.14 % | $ 463 B | ||
|
AbCellera Biologics
ABCL
|
$ 14.59 | 0.4 % | $ 4.36 B | ||
|
Abeona Therapeutics
ABEO
|
$ 5.25 | 1.74 % | $ 278 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
$ 4.78 | 1.92 % | $ 916 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
$ 20.15 | 0.52 % | $ 3.39 B | ||
|
Achieve Life Sciences
ACHV
|
$ 8.09 | 5.2 % | $ 353 M | ||
|
AC Immune SA
ACIU
|
$ 2.62 | 0.77 % | $ 264 M | ||
|
Aclaris Therapeutics
ACRS
|
$ 5.26 | 0.85 % | $ 645 M | ||
|
Adagene
ADAG
|
$ 3.2 | 0.28 % | $ 189 M | ||
|
ADC Therapeutics SA
ADCT
|
$ 1.22 | 0.41 % | $ 155 M | ||
|
Adial Pharmaceuticals
ADIL
|
$ 4.01 | 0.48 % | $ 2.68 M | ||
|
ADMA Biologics
ADMA
|
$ 10.03 | 0.7 % | $ 2.39 B | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
$ 28.9 | 0.45 % | $ 4.38 B | ||
|
Agenus
AGEN
|
$ 9.93 | 0.4 % | $ 295 M | ||
|
AIM ImmunoTech
AIM
|
$ 0.18 | 1.51 % | $ 291 K | ||
|
Akebia Therapeutics
AKBA
|
$ 0.92 | 3.83 % | $ 237 M | ||
|
Akari Therapeutics, Plc
AKTX
|
$ 9.3 | 3.4 % | $ 626 B | ||
|
Aldeyra Therapeutics
ALDX
|
$ 1.23 | 13.79 % | $ 73.9 M | ||
|
Alector
ALEC
|
$ 1.85 | 0.27 % | $ 191 M | ||
|
Aligos Therapeutics
ALGS
|
$ 5.63 | 0.18 % | $ 55.7 M | ||
|
Alkermes plc
ALKS
|
$ 40.52 | 1.62 % | $ 6.67 B | ||
|
Allogene Therapeutics
ALLO
|
$ 1.6 | 0.57 % | $ 353 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
$ 246.74 | 2.55 % | $ 32.3 B | ||
|
Altimmune
ALT
|
$ 2.86 | 0.34 % | $ 252 M | ||
|
ALX Oncology Holdings
ALXO
|
$ 1.39 | 2.96 % | $ 74.6 M | ||
|
Amgen
AMGN
|
$ 421.51 | 0.07 % | $ 227 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
$ 25.81 | 0.09 % | $ 1.21 B | ||
|
Amneal Pharmaceuticals
AMRX
|
$ 20.14 | 0.22 % | $ 6.31 B | ||
|
AnaptysBio
ANAB
|
$ 50.26 | 0.98 % | $ 1.46 B | ||
|
Anika Therapeutics
ANIK
|
$ 19.66 | 0.1 % | $ 282 M | ||
|
ANI Pharmaceuticals
ANIP
|
$ 72.65 | 0.04 % | $ 1.46 B | ||
|
Annexon
ANNX
|
$ 4.23 | 2.42 % | $ 656 M | ||
|
Annovis Bio
ANVS
|
$ 1.27 | 1.92 % | $ 26.1 M | ||
|
Aprea Therapeutics
APRE
|
$ 0.75 | 0.16 % | $ 4.9 M | ||
|
Aptevo Therapeutics
APVO
|
$ 1.82 | 0.54 % | $ 574 K | ||
|
Aquestive Therapeutics
AQST
|
$ 4.63 | 0.11 % | $ 495 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
$ 13.69 | 0.36 % | $ 375 M | ||
|
Ardelyx
ARDX
|
$ 3.42 | 0.88 % | $ 824 M | ||
|
argenx SE
ARGX
|
$ 958.91 | 1.33 % | $ 58.8 B | ||
|
Armata Pharmaceuticals
ARMP
|
$ 3.67 | 2.23 % | $ 133 M | ||
|
Arcutis Biotherapeutics
ARQT
|
$ 26.43 | 0.09 % | $ 3.36 B | ||
|
Artelo Biosciences
ARTL
|
$ 4.04 | 1.11 % | $ 764 K | ||
|
Arvinas
ARVN
|
$ 7.74 | 3.13 % | $ 549 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
$ 65.45 | 1.21 % | $ 8.75 B | ||
|
Assembly Biosciences
ASMB
|
$ 23.49 | 0.04 % | $ 263 M | ||
|
Ascendis Pharma A/S
ASND
|
$ 227.83 | 0.5 % | $ 13.8 B |